Loading...

ALK-Abelló A/S

AKBLFPNK
Healthcare
Biotechnology
$30.44
$0.00(0.00%)

ALK-Abelló A/S (AKBLF) Company Profile & Overview

Explore ALK-Abelló A/S’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

ALK-Abelló A/S (AKBLF) Company Profile & Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

SectorHealthcare
IndustryBiotechnology
CEOPeter Halling

Contact Information

45 45 74 75 76
Boge Alle 6-8, Horsholm, 2970

Company Facts

2,736 Employees
IPO DateNov 16, 2009
CountryDK
Actively Trading

Frequently Asked Questions

;